Freenome Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
430
- Latest Deal Type
-
Series F
- Latest Deal Amount
-
$254M
- Investors
-
60
Freenome General Information
Description
Developer of a multi-omics platform designed to detect cancer at an early stage through a routine blood draw. The company's platform uses a proprietary algorithm method that aims to reinvent disease management through systematized early detection and intervention of disease screenings, enabling doctors to treat cancer and other diseases at manageable stages.
Contact Information
Website
www.freenome.comCorporate Office
- 279 East Grand Avenue
- 5th Floor
- San Francisco, CA 94080
- United States
Corporate Office
- 279 East Grand Avenue
- 5th Floor
- San Francisco, CA 94080
- United States
Freenome Timeline
Freenome Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series F) | 15-Feb-2024 | $254M | Completed | Clinical Trials - General | ||
| 9. Later Stage VC (Series E) | 11-Jan-2022 | Completed | Clinical Trials - General | |||
| 8. Later Stage VC (Series D) | 07-Dec-2021 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series C) | 22-Jul-2020 | Completed | Clinical Trials - General | |||
| 6. Later Stage VC (Series B) | 25-Jun-2019 | Completed | Startup | |||
| 5. Early Stage VC (Series A) | 14-Aug-2017 | Completed | Startup | |||
| 4. Seed Round | 07-Jun-2016 | Completed | Startup | |||
| 3. Seed Round | 28-Oct-2015 | Completed | Startup | |||
| 2. Accelerator/Incubator | 24-Aug-2015 | Completed | Startup | |||
| 1. Grant | 13-Jan-2014 | $698K | Completed | Startup |
Freenome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed-2 | 9,092,395 | $0.000100 | 6% | $0.61 | $0.61 | 1x | $0.61 | 3.06% |
| Seed-1 | 3,360,000 | $0.000100 | 6% | $0.24 | $0.24 | 1x | $0.24 | 1.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Freenome Comparisons
Industry
Financing
Details
Freenome Competitors (15)
One of Freenome’s 15 competitors is GenoSpace, a Corporate Backed or Acquired company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GenoSpace | Corporate Backed or Acquired | Boston, MA | ||||
| Boreal Genomics | Formerly VC-backed | Vancouver, Canada | ||||
| JvionAI | Formerly PE-Backed | Johns Creek, GA | ||||
| Adaptive Biotechnologies | Formerly VC-backed | Seattle, WA | ||||
| Epic Sciences | Venture Capital-Backed | San Diego, CA |
Freenome Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
News about Freenome
Dive into recent articles by PitchBook offering invaluable insights and context.
Freenome Patents
Freenome Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250122563-A1 | Methods and compositions of nucleic acid molecule enrichment for sequencing | Pending | 23-Jun-2022 | ||
| EP-4544075-A2 | Methods and compositions of nucleic acid molecule enrichment for sequencing | Pending | 23-Jun-2022 | ||
| EP-4536845-A1 | Sequence process validation methods and compositions | Pending | 13-Jun-2022 | ||
| US-20250122575-A1 | Sequence process validation methods and compositions | Pending | 13-Jun-2022 | ||
| AU-2023278176-A1 | Markers for the early detection of colon cell proliferative disorders | Pending | 03-Jun-2022 | G01N33/57419 |
Freenome Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Freenome Investors (60)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Microsoft | Corporation | Minority | ||
| Quest Diagnostics | Corporation | Minority | ||
| Squarepoint Capital | Hedge Fund | Minority | ||
| Standish Spring Investments | Venture Capital | Minority | ||
| ARK Venture Fund | Venture Capital | Minority |
Freenome Acquisitions (2)
Freenome’s most recent deal was a Merger/Acquisition with Oncimmune (Immunodiagnostics Developer) for . The deal was made on 22-May-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oncimmune (Immunodiagnostics Developer) | 22-May-2023 | Merger/Acquisition | Biotechnology | ||
| Oncimmune Holdings (Oncimmune Europe and Oncimmune Limited) | 22-May-2023 | Merger/Acquisition | Laboratory Services (Healthcare) |
Freenome FAQs
-
When was Freenome founded?
Freenome was founded in 2014.
-
Where is Freenome headquartered?
Freenome is headquartered in San Francisco, CA.
-
What is the size of Freenome?
Freenome has 430 total employees.
-
What industry is Freenome in?
Freenome’s primary industry is Decision/Risk Analysis.
-
Is Freenome a private or public company?
Freenome is a Private company.
-
What is the current valuation of Freenome?
The current valuation of Freenome is .
-
What is Freenome’s current revenue?
The current revenue for Freenome is .
-
How much funding has Freenome raised over time?
Freenome has raised $1.35B.
-
Who are Freenome’s investors?
Microsoft, Quest Diagnostics, Squarepoint Capital, Standish Spring Investments, and ARK Venture Fund are 5 of 60 investors who have invested in Freenome.
-
Who are Freenome’s competitors?
GenoSpace, Boreal Genomics, JvionAI, Adaptive Biotechnologies, and Epic Sciences are some of the 15 competitors of Freenome.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
